title: The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.
abstract: The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sjögren's, Behçet's, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.
authors: Oregon Health and Science University, Portland, OR, USA. winthrop@ohsu.edu.
authors: Kevin L
authors: KL
authors: Winthrop
authors: Stanford University School of Medicine, Portola Valley, CA, USA.
authors: Vibeke
authors: V
authors: Strand
authors: Leiden University Medical Center, Meerssen, The Netherlands.
authors: Désiréé M
authors: DM
authors: van der Heijde
authors: Swedish Medical Center and University of Washington, Seattle, WA, USA.
authors: Philip J
authors: PJ
authors: Mease
authors: Hospital for Special Surgery, New York, NY, USA.
authors: Mary K
authors: MK
authors: Crow
authors: Brigham and Women's Hospital, Boston, MA, USA.
authors: Michael
authors: M
authors: Weinblatt
authors: Columbia University, New York, NY, USA.
authors: Joan M
authors: JM
authors: Bathon
authors: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors: Maya H
authors: MH
authors: Buch
authors: Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
authors: Gerd R
authors: GR
authors: Burmester
authors: Hôpital Cochin, Paris, France.
authors: Maxime
authors: M
authors: Dougados
authors: University of Massachusetts Medical School, Worcester, MA, USA.
authors: Jonathan
authors: J
authors: Kay
authors: Paris-Sud University, Le Kremlin Bicetre, France.
authors: Xavier
authors: X
authors: Mariette
authors: Leiden University Medical Center, Leiden, Netherlands.
authors: Ferry C
authors: FC
authors: Breedveld
authors: University of Erlangen, Erlangen, Germany.
authors: Joachim R
authors: JR
authors: Kalden
authors: Vienna Medical Academy, Vienna, Austria.
authors: Josef S
authors: JS
authors: Smolen
authors: University of California, Los Angeles Medical Center, Los Angeles, CA, USA.
authors: Daniel E
authors: DE
authors: Furst
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research; D018450:Disease Progression; D006292:Health Priorities; D006801:Humans; D058990:Molecular Targeted Therapy; D020380:Needs Assessment; D012074:Remission Induction; D012107:Research Design; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012219:Rheumatology; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents